News Conference News ESC 2025 MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide Caitlin E. Cox August 30, 2025
News Conference News ESC Heart Failure 2024 SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM Michael O'Riordan May 13, 2024
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News AHA 2023 Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD Todd Neale November 09, 2023
News Conference News ESC 2023 ESC Cardiomyopathy Guidelines Span Range of Phenotypes Yael L. Maxwell August 31, 2023
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward Todd Neale November 16, 2021
News Conference News ESC 2020 EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class Michael O'Riordan August 29, 2020
News Conference News TCT 2018 ULTIMATE: IVUS Superior to Angiography at Guiding PCI, With Less TVF by 1 Year Lucy Hicks September 24, 2018
News Conference News AHA 2017 Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins Caitlin E. Cox November 14, 2017
News Conference News ACC 2017 Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports Michael O'Riordan March 24, 2017